Bei Akademie registrieren
AbbVie Inc., US00287Y1091

AbbVie Inc. stock at EUR 253.20 ahead of the Xetra open: pharmaceutical group little changed

Published on 10/19/2026 at 07:47 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
AbbVie develops medicines through pharmaceutical research and development. At Lang & Schwarz the stock trades pre-market at EUR 253.20 on October 19, 2026, 0.04 percent above the Xetra close of October 16, 2026.

Business model and price

  • AbbVie develops medicines through pharmaceutical research and development.
  • The home market is the S&P 500 in the United States on October 19, 2026.
  • AbbVie Inc. stock trades pre-market at EUR 253.20 at 7:45 a.m. CEST at Lang & Schwarz on October 19, 2026, 0.04 percent above the Xetra close of October 16, 2026.
Isometrische 3D-Illustration des Drug-Discovery-Prozesses von Molekülforschung bis Marktzulassung
AbbVie Inc. US00287Y1091 isometrische 3D Darstellung Drug Discovery Prozess von Molekül Studie bis Marktzulassung, Illustration mit AI erstellt.

AbbVie is a pharmaceutical company that develops medicines through research and development, according to the company’s website. AbbVie Inc. stock trades pre-market at EUR 253.20 at 7:45 a.m. CEST at Lang & Schwarz on October 19, 2026, 0.04 percent above the Xetra close of October 16, 2026 (EUR 253.10).

Ahead of the Xetra open

The stock is EUR plus 0.10 above the Xetra close of October 16, 2026. The further course from the Xetra open at 9:00 a.m. CEST is shown by the continuously updated real-time quote of AbbVie stock.

AbbVie and its market

AbbVie develops pharmaceutical products through research and development and collaboration with external innovation partners, as described on its company website. Market context: Market report S&P 500.

More news and analysis on AbbVie stock

Disclaimer...
en | US00287Y1091 | ABBVIE INC. | boerse | 70357534 | bgmi